A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer

被引：0
|
作者：
Wu, Jiong
Zhang, Jian
Tong, Zhongsheng
Wang, Yongsheng
Zhang, Qingyuan
Cheng, Qiao
Chen, Xin
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Second Peoples Hosp Yibin, Yibin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13091
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase Ib/II study to assess the safety and efficacy of PM8002/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer
    Wu, J.
    Zhang, J.
    Tong, Z.
    Zhang, Q.
    Wang, Y.
    Cheng, Q.
    Chen, X.
    Li, Z.
    Yin, Y.
    Du, Y.
    Meng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S361 - S361
  • [2] A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Wu, Jiong
    Zhang, Jian
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Yong-Sheng
    Cheng, Qiao
    Chen, Xin
    Li, Zhihua
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [4] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
    Kang, Connie
    Syed, Yahiya Y.
    DRUGS, 2020, 80 (06) : 601 - 607
  • [6] Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
    Connie Kang
    Yahiya Y. Syed
    Drugs, 2020, 80 : 601 - 607
  • [7] IMpassion130: Atezolizumab and nab-Paclitaxel Combination in Patients with triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (10) : 1076 - +
  • [8] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    O'Sullivan, Hazel
    Collins, Dearbhaile
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 986 - 986
  • [9] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S. -A.
    Wright, G. Shaw
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2108 - 2121
  • [10] Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
    Arpino, Grazia
    De Placido, Sabino
    De Angelis, Carmine
    ANTI-CANCER DRUGS, 2015, 26 (01) : 117 - 122
12345